[Neuroprotective effects of succinate-containing antihypoxante reamberine in treatment of patients with toxicohypoxic brain injury].
As a result of survey in process of treatment of 60 patients with severe acute poisoning complicated by the toxic-hypoxic brain edema, found that inclusion of reamberin (antihypoxant containing succinate) in basic therapy leads to increase levels of the antioxidant defense system, decrease lipid peroxidation and reduce NR2A titers of autoantibodies.  Reduction of degree of toxic-hypoxic encephalopathy promotes improving the clinical course, manifested shortened duration of coma and hospital bad days.
Kh V
KhV
Batotsyrenov
G A
GA
Livanov
G V
GV
Shestova
L D
LD
Tsvetnova
V D
VD
Velikova
V G
VG
Bazarova
D000328:Adult; D000975:Antioxidants / Q000378:metabolism*; D001930:Brain Injuries / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D003128:Coma / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018696:Neuroprotective Agents; D020258:Neurotoxicity Syndromes / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D011041:Poisoning / Q000150:complications*; D018091:Receptors, AMPA / Q000097:blood; D016194:Receptors, N-Methyl-D-Aspartate / Q000097:blood; D013386:Succinates / Q000008:administration & dosage*
D000975:Antioxidants; D018696:Neuroprotective Agents; C549374:Reamberin; D018091:Receptors, AMPA; D016194:Receptors, N-Methyl-D-Aspartate; D013386:Succinates; D008536:Meglumine